Search. Learn. Save

Platform for Pharmaceutical Products for Healthcare Professionals
Search By
☰ Generic Formulas

Generic Formulas X

Eltrombopag Olamine

Eltrombopag Olamine

Introduction

Eltrombopag olamine is an innovative drug that belongs to the class of thrombopoietin receptor agonists. It has shown great promise in treating several hematological conditions, primarily those involving low platelet counts. It is an oral medication that has become a significant treatment option for immune thrombocytopenia (ITP), chronic hepatitis C-associated thrombocytopenia, and severe aplastic anemia, offering new hope to patients suffering from these potentially life-threatening disorders. Eltrombopag olamine is known for its ability to stimulate platelet production in the bone marrow by binding to and activating the thrombopoietin receptor. Thrombopoietin (TPO) is a natural hormone that plays a crucial role in the production of platelets, the blood cells essential for clotting. The use of eltrombopag olamine in the treatment of conditions characterized by low platelet counts represents a milestone in hematology, as it provides an oral, convenient alternative to more invasive treatments, including steroids and splenectomy.

Pharmacology of Eltrombopag Olamine

Mechanism of Action

Eltrombopag olamine works by stimulating the thrombopoietin receptor (c-MPL), which is primarily located on megakaryocytes (the cells in the bone marrow responsible for producing platelets). Thrombopoietin (TPO) normally binds to this receptor, leading to megakaryocyte proliferation, maturation, and subsequent platelet production.

By mimicking the action of thrombopoietin, eltrombopag olamine directly activates the thrombopoietin receptor, leading to increased megakaryocyte production, which in turn boosts the production of platelets. This action is especially beneficial in conditions where the body is unable to produce an adequate number of platelets, leading to thrombocytopenia (low platelet count). Importantly, eltrombopag olamine's mechanism is distinct from that of traditional treatments, such as corticosteroids or intravenous immunoglobulin (IVIG), which aim to modify the immune system or directly treat platelet destruction. Instead, eltrombopag stimulates the body’s natural platelet production process, thereby offering a non-immunosuppressive treatment option.

Pharmacokinetics

The pharmacokinetics of eltrombopag olamine are crucial for understanding its effectiveness and appropriate dosing regimen.

  • Absorption: After oral administration, eltrombopag is rapidly absorbed from the gastrointestinal tract. Its peak plasma concentration occurs within 3 to 6 hours of dosing.

  • Bioavailability: Eltrombopag has a high bioavailability of approximately 60% when taken on an empty stomach. Food can impact its absorption, with high-fat meals reducing its bioavailability by approximately 50%.

  • Distribution: Eltrombopag is highly bound to plasma proteins (about 99%), and it is widely distributed throughout the body, including in the liver, which is crucial for its metabolism.

  • Metabolism: Eltrombopag is metabolized in the liver by cytochrome P450 enzymes, particularly CYP1A2 and CYP2C19. The drug undergoes extensive hepatic metabolism and forms metabolites that are generally inactive.

  • Excretion: The primary route of elimination for eltrombopag is through feces, with a minor portion being excreted in the urine. Its elimination half-life is relatively long, around 21 to 30 hours, which supports once-daily dosing.

Given these pharmacokinetic properties, eltrombopag's effectiveness can be influenced by dietary factors, the presence of liver impairment, and interactions with other medications that affect liver enzymes. As such, careful monitoring of liver function is required during treatment.

Clinical Applications of Eltrombopag Olamine

Eltrombopag olamine has been approved for use in several hematologic conditions, particularly those involving low platelet counts. These include:

1. Immune Thrombocytopenia (ITP)

Immune thrombocytopenia (ITP) is a disorder characterized by an abnormally low platelet count due to the immune system mistakenly attacking and destroying the body's own platelets. This leads to an increased risk of bleeding and bruising.

Eltrombopag olamine is used in chronic ITP (lasting for at least 6 months), where patients experience refractory thrombocytopenia—meaning their low platelet count does not respond to traditional therapies, such as corticosteroids, IV immunoglobulin (IVIG), or splenectomy. Eltrombopag works by stimulating megakaryocyte production in the bone marrow, leading to increased platelet production and potentially reducing the need for other more invasive or immunosuppressive treatments.

Studies have demonstrated that eltrombopag significantly increases platelet counts in patients with ITP who have not responded adequately to previous treatments. Eltrombopag is typically used as a second-line treatment when other therapies have failed, and its effectiveness in improving platelet counts has been well-documented in clinical trials.

2. Chronic Hepatitis C-Associated Thrombocytopenia

Hepatitis C is a viral infection that can lead to chronic liver disease and cirrhosis. One of the complications of hepatitis C is thrombocytopenia, as liver dysfunction impacts platelet production.

Eltrombopag is used to treat thrombocytopenia associated with chronic hepatitis C in patients who require interferon-based therapy. Chronic hepatitis C patients are often disqualified from receiving interferon-based treatments due to low platelet counts, which can lead to delayed treatment or ineffective outcomes.

Eltrombopag increases platelet production, thereby allowing patients with hepatitis C to undergo interferon-based therapy without the risk of bleeding complications. In clinical trials, eltrombopag has been shown to improve platelet counts in these patients, facilitating hepatitis C treatment and improving overall outcomes.

3. Severe Aplastic Anemia

Severe aplastic anemia is a life-threatening condition in which the bone marrow fails to produce enough blood cells, including platelets, leading to anemia, thrombocytopenia, and neutropenia. It is most commonly treated with bone marrow transplants or immunosuppressive therapy, but these treatments are not always effective for all patients.

Eltrombopag has been investigated as a treatment for severe aplastic anemia. Clinical studies have demonstrated that eltrombopag, when used in combination with antithymocyte globulin (ATG), can increase platelet counts and improve hematopoiesis in some patients with severe aplastic anemia, particularly those who are not suitable candidates for stem cell transplants.

While eltrombopag is not a first-line treatment for this condition, its use offers a valuable alternative for patients with non-severe aplastic anemia or those who have failed first-line treatments.

Dosing and Administration

Eltrombopag is available as oral tablets and granules. The dosage and administration guidelines vary based on the condition being treated.

1. Immune Thrombocytopenia (ITP)

  • Initial dose: The usual starting dose for ITP is 50 mg once daily. The dose may be adjusted based on platelet response and side effects.

  • Platelet count monitoring: Regular monitoring of platelet counts is recommended. The dose may be reduced or discontinued based on platelet counts or adverse effects.

  • Duration of therapy: The treatment duration for ITP is generally individualized, depending on patient response and clinical needs.

2. Chronic Hepatitis C-Associated Thrombocytopenia

  • Initial dose: The starting dose for hepatitis C-related thrombocytopenia is usually 25 mg once daily.

  • Platelet count monitoring: Platelet counts should be checked regularly to ensure that the patient’s count reaches an adequate level to proceed with interferon-based therapy.

  • Duration of therapy: The duration is generally dependent on the patient’s response to both eltrombopag and hepatitis C treatment.

3. Severe Aplastic Anemia

  • Initial dose: The recommended starting dose for severe aplastic anemia is 50 mg once daily.

  • Combination therapy: Eltrombopag is used in combination with antithymocyte globulin (ATG) for severe aplastic anemia.

  • Monitoring: Patients should be monitored for hematological response, including platelet count, and for adverse effects.

Side Effects of Eltrombopag Olamine

Eltrombopag, like all medications, comes with potential side effects. Some of the most common side effects include:

Common Side Effects:

  • Headache

  • Fatigue

  • Nausea

  • Abdominal pain

  • Dyspepsia (indigestion)

  • Insomnia

  • Elevated liver enzymes

Serious Side Effects:

  • Hepatotoxicity: Eltrombopag has been associated with elevated liver enzymes and liver dysfunction, which can lead to liver failure in rare cases. Regular liver function tests are recommended during treatment.

  • Bone marrow fibrosis: Long-term use of eltrombopag may increase the risk of bone marrow fibrosis, a condition that can impair bone marrow function.

  • Risk of clotting: Because eltrombopag increases platelet production, there may be an increased risk of thrombosis (blood clots), especially in patients with underlying risk factors for clotting.

Patients should undergo regular monitoring of liver function and platelet counts, and adjustments to dosage should be made as necessary to avoid complications.

Conclusion

Eltrombopag olamine represents a significant advancement in the treatment of thrombocytopenia in a variety of clinical settings. Whether it is used to treat immune thrombocytopenia, chronic hepatitis C-associated thrombocytopenia, or severe aplastic anemia, eltrombopag has proven to be an effective and non-immunosuppressive alternative to traditional therapies. Its ability to stimulate platelet production via the thrombopoietin receptor offers a unique mechanism of action that has provided relief for patients who previously had few options. However, like all medications, it requires careful monitoring for potential side effects, particularly those involving liver function and hematologic response.